InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.035 0.003 (7.89%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Appendix 4C - quarterly 25 Oct 2019 4:34PM $0.023 $0.035 risen by 52.17%
$19 US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy 23 Oct 2019 9:44AM $0.021 $0.035 risen by 66.67%
$19 Change of Director's Interest Notice - AH 21 Oct 2019 3:09PM $0.021 $0.035 risen by 66.67%
$19 CF33 Oncolytic Virus Clinical Trial Program Update 21 Oct 2019 9:15AM $0.021 $0.035 risen by 66.67%
$19 Appendix 3B and 708A Notice 18 Oct 2019 11:04AM $0.021 $0.035 risen by 66.67%
$19 Yuman Fong, MD to Chair Imugene Oncolytic Virotherapy SAB 17 Oct 2019 10:26AM $0.021 $0.035 risen by 66.67%
$19 Notice of Extraordinary General Meeting/Proxy Form 14 Oct 2019 4:40PM $0.020 $0.035 risen by 75%
$19 Notice of UMP Facility to Eligible Shareholders 9 Oct 2019 11:08AM $0.020 $0.035 risen by 75%
$19 Share Sale Facility for Holders of Unmarketable Parcels 4 Oct 2019 2:57PM $0.021 $0.035 risen by 66.67%
$19 Notice of Annual General Meeting/Proxy Form 4 Oct 2019 12:35PM $0.021 $0.035 risen by 66.67%
$19 Imugene Cancer Vaccine Combinations Presented at ESMO 1 Oct 2019 9:30AM $0.021 $0.035 risen by 66.67%
$19 Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO 1 Oct 2019 9:19AM $0.021 $0.035 risen by 66.67%
$19 Appendix 4G 30 Aug 2019 4:57PM $0.021 $0.035 risen by 66.67%
$19 Corporate Governance Statement 30 Aug 2019 4:56PM $0.021 $0.035 risen by 66.67%
$19 Appendix 4E & Annual Report to shareholders 30 Aug 2019 4:53PM $0.021 $0.035 risen by 66.67%
$19 Appendix 4C - quarterly 26 Jul 2019 1:25PM $0.023 $0.035 risen by 52.17%
$19 2019 Bioshares Presentation 26 Jul 2019 9:52AM $0.022 $0.035 risen by 59.09%
$19 Investor update call details 15 Jul 2019 10:21AM $0.016 $0.035 risen by 118.75%
$19 Investor Presentation - Proposed Acquisition 15 Jul 2019 9:25AM $0.016 $0.035 risen by 118.75%
$19 Imugene Enhances Portfolio with Compelling Oncolytic Virus 15 Jul 2019 8:34AM $0.016 $0.035 risen by 118.75%
$19 New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI 8 Jul 2019 9:13AM $0.015 $0.035 risen by 133.33%
$19 Appendix 3B and 708A Notice 27 Jun 2019 1:51PM $0.015 $0.035 risen by 133.33%
$19 Updated Phase 1b HER-Vaxx data presented at ASCO 4 Jun 2019 9:16AM $0.017 $0.035 risen by 105.88%
$19 Initial Director's Interest Notice - JE 20 May 2019 9:46AM $0.017 $0.035 risen by 105.88%
$19 Global Biotechnology & VC Executive Joins Imugene Board 20 May 2019 9:39AM $0.017 $0.035 risen by 105.88%

776 - 800 of 1209 results

Page 32 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.